Table 1.
The primary characteristics of the eligible studies in more detail
| Reference | Country | Histology | Treatment (n of patients)
|
Dose (mg/m2) | Overall survival
|
Metastasis (n of patients)*
|
Recurrence (n of patients)*
|
||
|---|---|---|---|---|---|---|---|---|---|
| CRT+S/SA | Follow-up (mo) | Intervention | Control | Intervention | Control | ||||
| Urba et al,6 2001 | USA | SCC and AC | 47/50 | C:20; F:300; 35 Gy | 98 | ||||
| Tepper et al,7 2008 | USA | SCC and AC | 30/26 | C:100; F:1,000; 41.5 Gy | 60 | 9 | 12 | ||
| van Hagen et al,9 2012 | The Netherlands | SCC and AC | 178/188 | Carboplatin: 2 mg/mL/min; P:50; 41.4 Gy | 45.4 | 62 | 188 | ||
| Burmeister et al,12 2005 | Australia | SCC and AC | 128/128 | C:80; F:1,800; 35 Gy | 65 | 48 | 54 | 61 | 68 |
| Lv et al,8 2010 | China | SCC | 80/80 | P:135 d1, 22; C:20 d1–3 and 22–25; 40 Gy | 45 | ||||
| Mariette et al,10 2014 | France | SCC | 98/97 | C:75 d1; F:800 d1–4; 45 Gy | 93.6 | 22 | 28 | 28 | 43 |
| Lee et al,11 2004 | Korea | SCC | 51/50 | C:60; F:1,000; 45.6 Gy | 25 | 6 | 12 | 19 | 18 |
*
Note: Data was pooled from different trials with different inclusion criteria, patients might have differential criteria for metastasis and recurrence; there is significant heterogeneity among included studies.
Abbreviations: AC, adenocarcinoma; C, cisplatin; CRT, chemoradiotherapy; d, day; F, fluorouracil; mo, months; P, paclitaxel; S, surgery; SA, surgery alone; SCC, squamous cell carcinoma.